Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-ii crawled time : 06:00 save search
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
Published: 2023-07-11 (Crawled : 06:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
iph6401 trial
COVID-19 Changed the Biopharma Industry - and There's No Going Back
Published: 2022-03-09 (Crawled : 06:00) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: 5.73%
H: 0.0%
C: 0.0%
covid-19 biopharma covid
Janssen is Taking a Big Swing at Autoantibody-Driven Diseases
Published: 2022-02-28 (Crawled : 06:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.79%
H: 0.0%
C: 0.0%
disease antibody
FDA Action Alert: Immunocore, Reata, CTI, Gilead and Legend/Janssen
Published: 2022-02-21 (Crawled : 06:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
fda
The Epidemic of Obesity and its Impact on the Immune System
Published: 2022-02-01 (Crawled : 06:00) - biospace.com/
CWBR | $0.9003 -11.88% 360
|
Health Technology
|
| O: 5.52%
H: 0.0%
C: -1.51%
obesity system
Clinical Catch-Up: January 24 – January 28
Published: 2022-01-31 (Crawled : 06:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
Biopharma is Tackling Misfolding Proteins in Parkinson’s Disease
Published: 2021-12-02 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.19%
H: 0.0%
C: 0.0%
biopharma parkinson disease
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy
Published: 2021-04-20 (Crawled : 06:00) - biospace.com/
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.01%
H: 2.16%
C: 1.56%
disease alzheimer phase 2 therapy phase 2b research trial alzheimer’s alzheimer's disease alzheimer's lecanemab
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.